Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report.

BMC cancer - 7 Jul 2016

Casadei Gardini Andrea, Chiadini Elisa, Faloppi Luca, Marisi Giorgia, Delmonte Angelo, Scartozzi Mario, Loretelli Cristian, Lucchesi Alessandro, Oboldi Devil, Dubini Alessandra, Frassineti Giovanni Luca, Ulivi Paola

Abstract excerpt

BACKGROUND: Sorafenib is a multi-targeted kinase inhibitor with a demonstrated activity in renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC), and it is currently used for the treatment of these pathologies. Ongoing clinical trials are studying its activity in other malignancies, such as non-small-cell lung cancer (NSCLC). However, no biological marker is known to define either the sensitivity or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Hepatocellular
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Liver Neoplasms

Share to Neoplasms, Multiple Primary

Share to Niacinamide

Share to Phenylurea Compounds

Share to Proto-Oncogene Proteins B-raf

Share to Sorafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 27388325
DOI: 10.1186/s12885-016-2463-2
PMCID: PMC4937544

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report.PMID 27388325Read ↗

A significant response to sorafenib in a woman with advanced lung adenocarcinoma and a BRAF non-V600 mutation.Semantic proximity Read ↗

A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806).Semantic proximity Read ↗

Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib.Semantic proximity Read ↗

Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report.Semantic proximity Read ↗

Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens.Semantic proximity Read ↗

A rare case of squamous cell carcinoma of the lung harbouring ALK and BRAF activating mutations.Semantic proximity Read ↗

A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805).Semantic proximity Read ↗

A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation.Semantic proximity Read ↗

A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib.Semantic proximity Read ↗

A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer.Semantic proximity Read ↗

Sorafenib efficacy in thymic carcinomas seems not to require c-KIT or PDGFR-alpha mutations.Semantic proximity Read ↗

SETD1A augments sorafenib primary resistance via activating YAP in hepatocellular carcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.